Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

CSL300

Phase 1Small molecule

1

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

End-Stage Kidney DiseaseRecruiting

End-Stage Kidney DiseasePhase 1

Recruiting

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

End-Stage Kidney Disease

NCT07619820

Q2 2029

PreclinicalRecruiting

End-Stage Kidney Disease

NCT05485961

Clinical

Trials by Indication[1]

End-Stage Kidney Disease2 trials

A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis

Recruiting· CSL Behring logo

CSL Behring·Preclinical·NCT05485961·3,110 enrolled

A Phase 1b, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease Undergoing Dialysis

Recruiting· CSL Behring logo

CSL Behring·Phase 1·NCT07619820·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CSL300. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CSL300 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CSL300. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CSL Behring

Related News